Xilio Therapeutics, Inc. Common Stock
Symbol: XLO (NASDAQ)
Company Description:
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
- Today's Open: $0.8206
- Today's High: $0.861
- Today's Low: $0.823
- Today's Volume: 477.32K
- Yesterday Close: $0.8427
- Yesterday High: $0.9099
- Yesterday Low: $0.8318
- Yesterday Volume: 467.90K
- Last Min Volume: 100
- Last Min High: $0.829
- Last Min Low: $0.829
- Last Min VWAP: $0.829
- Name: Xilio Therapeutics, Inc. Common Stock
- Website: https://www.xiliotx.com
- Listed Date: 2021-10-22
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001840233
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $43.68M
- Round Lot: 100
- Outstanding Shares: 51.83M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-09 | 8-K | View |
2025-08-28 | 8-K | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | 10-Q | View |
2025-08-14 | 8-K | View |
2025-06-18 | 4 | View |
2025-06-18 | 4 | View |
2025-06-18 | 4/A | View |
2025-06-17 | SCHEDULE 13G | View |
2025-06-12 | SCHEDULE 13G | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |
2025-06-12 | 4 | View |